Safety of Kidney Transplantation from Donors with HIV Infection. Reply [0.03%]
论来自HIV感染供者的肾脏移植的安全性：回信
Christine M Durand,Dorry L Segev,Andrew D Redd
Christine M Durand
Ting Chen,Guanning Shang
Ting Chen
Kevin L Lin,Samantha Shekar,Megan Crumbaker et al.
Kevin L Lin et al.
Nathan O Stitziel
Nathan O Stitziel
Case 1-2025: A 35-Year-Old Woman with Shortness of Breath and Edema in the Legs [0.03%]
病例分析2025：一名35岁女性患者，表现为呼吸困难及双下肢水肿
Jessica S Tangren,Anushya Jeyabalan,Veronica E Klepeis
Jessica S Tangren
Tin Yan Lee,Wan Hang Lau
Tin Yan Lee
Antonio Cannata,Theresa A McDonagh
Antonio Cannata
Amanda J Ullman,Deanne August,Tricia M Kleidon et al.
Amanda J Ullman et al.
Background: New catheter materials for peripherally inserted central catheters (PICCs) may reduce the risk of device failure due to infectious, thrombotic, and catheter occlusion events. However, data from randomized tria...
Comparative Study
The New England journal of medicine. 2025 Jan 9;392(2):161-172. DOI:10.1056/NEJMoa2406815 2025
Clearance of Driver Mutations after Transplantation for Myelofibrosis [0.03%]
异基因移植治疗骨髓纤维化患者时驱动基因突变的清除
Nico Gagelmann,Marie Quarder,Anita Badbaran et al.
Nico Gagelmann et al.
Background: Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease, but the role of mutation clearance afte...
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma [0.03%]
Talquetamab联合Teclistamab治疗复发或难治性多发性骨髓瘤
Yael C Cohen,Hila Magen,Moshe Gatt et al.
Yael C Cohen et al.
Background: Talquetamab (anti-G protein-coupled receptor family C group 5 member D) and teclistamab (anti-B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and that have been appr...